Argenx - About the company
Argenx is a deadpooled company based in London (United Kingdom), founded in 2017. It operates as a Develops therapeutic antibodies for cancer. The company has 2372 active competitors, including 606 funded and 455 that have exited. Its top competitors include companies like Synthego, Harbour BioMed and Zymeworks.
Company Details
Argenx discovers, designs and develops innovative antibody therapeutics for treatments of cancer and autoimmune diseases and for its partners. The company uses llama immune system with antibody engineering called SIMPLE Antibody™ Platform to produce humanized antibodies. Currently, its ARGX-113 for autoimmune disease in Phase II trial, and the following candidates ARGX-110, ARGX-111, ARGX-115 are in Phase II, Phase I, and Phase I respectively for Oncology.
- Website
- argenxpharma.org
- Email ID
- *****@argenxpharma.org
- Phone Number
- +44 **********
Key Metrics
Sign up to download Argenx's company profile
Argenx's funding and investors
Argenx has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Argenx's Competitors and alternates
Top competitors of Argenx include Synthego, Harbour BioMed and Zymeworks. Here is the list of Top 10 competitors of Argenx, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Synthego 2012, Redwood City (United States), Acquired | Developer of CRISPR-engineered cell and gene therapies | $460M | 71/100 | |
2nd |  Harbour BioMed 2016, Shanghai (China), Public | Developer of antibody therapeutics in immunology and oncology disease | $313M | 71/100 | |
3rd | Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer | $146M | 70/100 | ||
4th | Agios Pharmaceuticals 2008, Cambridge (United States), Public | Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism | $120M | 70/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 69/100 | |
6th |  Hummingbird Bioscience 2015, Singapore (Singapore), Series C | Developer of antibody drugs for cancer treatment | $150M | 68/100 | |
7th |  Avidity Biosciences 2012, San Diego (United States), Acquired | RNA therapeutics innovator targeting muscle and other diseases with AOC platform | $143M | 68/100 | |
8th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 67/100 | |
9th | Savara Pharma 2008, Austin (United States), Public | Developer of therapeutics for rare respiratory diseases | $67.8M | 67/100 | |
10th | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 67/100 | |
3071st | Argenx 2017, London (United Kingdom), Deadpooled | Develops therapeutic antibodies for cancer | - | - | 15/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Argenx's competitors? Click here to see the top ones
Argenx's Investments and acquisitions
Argenx has made no investments or acquisitions yet.
Reports related to Argenx
Here is the latest report on Argenx's sector:
Are you a Founder ?
FAQs about Argenx
Explore our recently published companies
- Diviplanx - Unfunded company
- Morikan - Unfunded company
- Ambitecoventure - Unfunded company
- Kedaletelematics - Unfunded company
- Golfwarehouseuk - 2006 founded, Unfunded company
- Alaskamillandfeed - 2003 founded, Acquired company
